Managing Cerezyme Infusions

Although Cerezyme is not a cure for Type 1 Gaucher disease (it does not correct the underlying genetic defect), regular treatment can help reduce or relieve some signs and symptoms. In order to continue to benefit from the treatment, you need to receive ongoing intravenous infusions, even though you may feel better. If therapy stops, Gaucher cells may build up again and symptoms may come back.

Still, treatment with Cerezyme does not mean you should stop all daily activities. If an opportunity arises for you to take a vacation; go to camp, attend college, or make a permanent move, talk to your doctor about developing a plan for treatment while you are away.

After consulting with your doctor about your plans, contact Sanofi Genzyme Support Services to help with the logistics of your trip. They can help you find a proper facility or qualified health care provider to administer any necessary infusions, as well as to arrange for an appropriate supply of Cerezyme therapy at your destination. They can also help you find out if insurance will cover care while you are traveling.

As these arrangements can take several months to coordinate, it's best to make your plans well in advance of travel or a move.

Sanofi Genzyme Support Services

Managing a genetic disease is a lifetime commitment. From diagnosis to treatment, our dedicated team of professionals is available to provide disease education and help address your needs, including assistance with health insurance issues, all free of charge.

Access to these and other services is voluntary, and you are not obligated to begin treatment if you contact us. You and your doctor make all treatment-related decisions, and most importantly the privacy and security of your personal situation is always protected.

For more information, contact Sanofi Genzyme Support Services at 800-745-4447 (option 3)

Indication & Usage

Cerezyme® (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions:

  1. anemia (low red blood cell count)
  2. thrombocytopenia (low blood platelet count)
  3. bone disease
  4. hepatomegaly or splenomegaly (enlarged liver or spleen)

Important Safety Information

Approximately 15% of patients have developed immune responses (antibodies) to Cerezyme during the first year of therapy. These patients have a higher risk of an allergic reaction (hypersensitivity). Your doctor may periodically test for the presence of antibodies. Serious allergic reactions (anaphylaxis) have been reported in less than 1% of patients. Symptoms suggestive of allergic reaction happened in approximately 7% of patients, and include itching, flushing, hives, swelling, chest discomfort, shortness of breath, coughing, cyanosis (a bluish discoloration of the skin due to diminished oxygen), and low blood pressure. If you have had an allergic reaction to Cerezyme, you and your doctor should use caution if you continue to receive treatment with Cerezyme.

High blood pressure in the arteries of the lungs (pulmonary hypertension) and pneumonia have been observed in less than 1% of patients during treatment with Cerezyme. These are also known complications of Gaucher disease regardless of treatment. If you experience symptoms such as shortness of breath or chest pain, with or without fever, contact your doctor.

Approximately 14% of patients have experienced side effects related to treatment with Cerezyme. Some of these reactions occur at the site of injection such as discomfort, itching, burning, swelling or uninfected abscess. Other side effects, each of which was reported by less than 2% of patients, include nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and rapid heart rate. Temporary swelling in the legs has also been observed with drugs like Cerezyme.

Please see Full Prescribing Information (PDF).

You may report side effects to the FDA at 1-800-FDA-1088.

Reference 1. Data on file. Genzyme Corporation; Cambridge, MA.